Formulation and Development of Liposome for The Treatment of Gastric Cancer

Abstract

Gastric cancer(GC) one of the common cancer malignancies worldwide. It is on the second rank in death due to cancer worldwide. This high mortality rate is due to late or advance stage diagnosis of cancer; symptoms are begun at an advanced stage of malignancy. Its five-year survival rate is also less and different in all worldwide countries. Treatment of GC is necessary and also there are so many chemotherapies available in market. Problem with this therapy are so many life threatening adverse effect and development of resistance, there are so many project have been started to address such kind of problem. In this project we have also developed liposome of sorafenib for the treatment of gastric cancer. Sorafenib is multi tyrosin kinase inhibitor that is why less chances of development of resistance and also reported for the reverse the drug resistance. We have prepared liposome of sorafenib, as liposome has highest impact on oncology till date, furthermore it is biocompatible, less toxic and easily fabricated. Last but not least by surface fictionalization we can target it to specific site. As the outcome of this project we can get the increased therapeutic efficacy, bioavailability, specific tumor targeting by modifying drug delivery system and the drug loading percentage will also increase with stability, furthermore solubility enhancement of drug that all parameter give efficient therapeutic response with minimal adverse effect.